Effect of Over-the-Counter Fish-Oil Administration on Plasma Lp(a) Levels in an End-Stage Renal Disease Population

Effects of Omega-3 Fatty Acids on Serum Lipids, Lipoprotein (a), and Hematologic Factors in Hemodialysis Patients

“…This finding was in agreement with those of some previous studies in hemodialysis patients. [15][16][17] In contrast to our study, Herrmann et al 14 showed that omega-3 fatty acids supplement significantly reduced serum Lp (a) concentration in nonrenal failure patients. This disparity may be because of the fact that Herrmann et al's 14 research was conducted in nonrenal failure subjects and dosage of omega-3 fatty acids supplement was 8.5 g/d.…”

“…Some of these studies in nonuremic patients have shown that omega-3 fatty acids supplement could reduce serum Lp (a) concentration, 14 whereas other researches did not indicate these effects in hemodialysis patients. [15][16][17] In addition, limited studies on the effect of omega-3 fatty acids supplement on hematologic factors are available, and their results are controversial. Some studies showed that omega-3 fatty acids supplement increased blood hemoglobin 18 and reduced erythropoietin requirements, 19 whereas other studies did not indicate these effects in hemodialysis patients.…”

Lipoprotein (a) – An Overview

“…45% irrespective of the plasma concentration of Lp(a) [111]. This is in agreement with many other studies showing that fish oils only seem to be able to reduce Lp(a) in combination with other therapies [107] or moderate exercise [112] but not when used alone [113,114,115].…”

Effect of omega-3 fatty acid supplementation on serum lipids and vascular inflammation in patients with end-stage renal disease: a meta-analysis

“…During the initial electronic search, 285 manuscripts were identified, of which 243 were excluded including duplicates, study with other design, and unrelated studies. The full text of 42 manuscripts was retrieved, and after detailed evaluation, 23 RCTs including 20 datasets were finally selected for meta-analysis1112131415161718192021222324252627282930313233. No new eligible studies were identified in manual search.…”

“…The follow-up duration of RCTs ranged from 2 to 6 months, and the number of patients enrolled in individual RCT ranged from 15 to 206. Ten trials were conducted in Asia12141516242526273133, seven in America11181920283032, two in Europe172329, and one in Africa13. The quality of RCTs was assessed using the Jadad score34 (Table 1), and the scores more than 3 were regarded as high quality trials.…”